Differential expression of genes induced by resveratrol in human breast cancer cell lines

Nutrition and Cancer

Volumn 56, Issue 2, 2006, Pages 193-203

  Le Corre, Ludovic ^a   Chalabi, Nasséra ^a   Delort, Laetitia ^a   Bignon, Yves Jean ^a   Bernard Gallon, Dominique J ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; COMPLEMENTARY DNA; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; MESSENGER RNA; PHYTOESTROGEN; RESVERATROL;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER PREVENTION; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PHYTOCHEMISTRY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

EID: 33947270312     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5602_10     Document Type: Article

References (76)

1. Burns J, Yokota T, Ashihara H, Lean ME, and Crozier A: Plant foods and herbal sources of resveratrol. J Agric Food Chem 50, 3337-3340, 2002.
2. Fremont L: Biological effects of resveratrol. Life Sci 66, 663-673, 2000.
3. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, and Merillon JM: Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci 61, 2103-2110, 1997.
4. Kimura Y, Okuda H, and Arichi S: Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834, 275-278, 1985.
5. Chung MI, Teng CM, Cheng KL, Ko FN, and Lin CN: An antiplatelet principle of Veratrum formosanum. Planta Med 58, 274-276, 1992.
6. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, and Goldberg DM: The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235, 207-219, 1995.
7. Soleas GJ, Diamandis EP, and Goldberg DM: Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30, 91-113, 1997.
8. Le Corre L, Chalabi N, Delort L, Bignon YJ, and Bernard-Gallon DJ: Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49, 462-471, 2005.
9. Lee JE and Safe S: Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 62, 1113-1124, 2001.
10. Ciolino HP and Yeh GC: Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56, 760-767, 1999.
11. Banerjee S, Bueso-Ramos C, and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62, 4945-4954, 2002.
12. Kundu JK and Surh YJ: Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 555, 65-80, 2004.
13. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al.: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273, 21875-21882, 1998.
14. Mgbonyebi OP, Russo J, and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12, 865-869, 1998.
15. Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K et al.: Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J Cancer Res Clin Oncol 127, 258-264, 2001.
16. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, and Fernandez-Salguero PM: The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 64, 1375-1386, 2002.
17. Pozo-Guisado E, Lorenzo-Benayas MJ, and Fernandez-Salguero PM: Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 109, 167-173, 2004.
18. Gehm BD, McAndrews JM, Chien PY, and Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94, 14138-14143, 1997.
19. Bowers JL, Tyulmenkov VV, Jernigan SC, and Klinge CM: Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-3667, 2000.
20. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, and Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61, 7456-7463, 2001.
21. Dumitrescu RG and Cotarla 1: Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 9, 208-221, 2005.
22. Chabner BA, Boral AL, and Multani P: Transitional research: walking the bridge between idea and cure-seventeenth Bruce F. Cain Memorial Award lecture. Cancer Res 58, 4211-4216, 1998.
23. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100, 57-70, 2000.
24. Lane D: The promise of molecular oncology. Lancet 351 (Suppl 2), SI117-SI120, 1998.
25. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin OncollO, 1S-13S, 2002.
26. Le Corre L, Fustier P, Chalabi N, Bignon YJ, and Bernard-Gallon D: Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin Chim Acta 344, 115-121, 2004.
27. Fustier P, Le Corre L, Chalabi N, Vissac-Sabatier C, Communal Y, Bignon YJ, et al.: Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. Br J Cancer 89, 168-172, 2003.
28. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al.: Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250, 53-58, 1998.
29. Garrigues GE, Cho DR, Rubash HE, Goldring SR, Herndon JH, and Shanbhag AS: Gene expression clustering using self-organizing maps: analysis of the macrophage response to particulate biometrials. Biometrials 26, 2933-2945, 2005.
30. Tillmar L and Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. J Pancreas 5, 81-91, 2004.
31. Favy DA, Lafarge S, Rio P, Vissac C, Bignon YJ, and Bernard-Gallon D: Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. Biochem Biophys Res Commun 274, 73-78, 2000.
32. Narayanan BA, Narayanan NK, Re GG, and Nixon DW: Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 104, 204-212, 2003.
33. Narayanan BA, Narayanan NK, Stoner GD, and Bullock BP: Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci 70, 1821-1839, 2002.
34. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, et al: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158, 85-91, 2000.
35. Mahyar-Roemer M, Kohler H, and Roemer K: Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells. BMC Cancer 2, 27-35, 2002.
36. Park JW, Choi YJ, Jang MA, Lee YS, Jun DY, Suh SI, et al.: Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett 163, 43-49, 2001.
37. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220, 1997.
38. Negrini M, Sabbioni S, Haldar S, Possati L, Castagnoli A, Corallini A, et al.: Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res 54, 1818-1824, 1994.
39. Hsieh TC, Juan G, Darzynkiewicz Z, and Wu JM: Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59, 2596-2601, 1999.
40. Kim YA, Choi BT, Lee YT, Park DI, Rhee SH, Park KY, et al.: Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 11, 441-446, 2004.
41. Falck J, Mailand N, Syljuasen RG, Bartek J, and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847, 2001.
42. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, et al.: Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429, 2000.
43. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, et al.: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogens 12, 2315-2324, 1996.
44. Musgrove EA, Sarcevic B, and Sutherland RL: Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J Cell Biochem 60, 363-378, 1996.
45. Foster JS, Henley DC, Ahamed S, and Wimalasena J: Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 12, 320-327, 2001.
46. Takeda K, Matsuzawa A, Nishitoh H, and Ichijo H: Roles of MAPKKK ASK1 in stress-induced cell death. Cell Struct Funct 28, 23-29, 2003.
47. Oster SK, Ho CS, Soucie EL, and Penn LZ: The myc oncogene: Marvelousl Y Complex. Adv Cancer Res 84, 81-154, 2002.
48. Macleod K: Tumor suppressor genes. Curr Opin Genet Dev 10, 81-93, 2000.
49. Schmitz ML, Mattioli I, Buss H, and Kracht M: NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 5, 1348-1358, 2004.
50. Taddei I, Faraldo MM, Teuliere J, Deugnier MA, Thiery JP, and Glukhova MA: Integrins in mammary gland development and differentiation of mammary epithelium. J Mammary Gland Biol Neoplasia 8, 383-394, 2003.
51. Lundstrom A, Holmbom J, Lindqvist C, and Nordstrom T: The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun 250, 735-740, 1998.
52. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, et al.: The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 87, 336-342, 2000.
53. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al.: Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16, 1266-1268, 2002.
54. Nawrocki Raby B, Polette M, Gilles C, Clavel C, Strumane K, Matos M, et al.: Quantitative cell dispersion analysis: new test to measure tumor cell aggressiveness. Int J Cancer 93, 644-652, 2001.
55. Igura K, Ohta T, Kuroda Y, and Kaji K.: Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171, 11-16, 2001.
56. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844, 1993.
57. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-1530, 1997.
58. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267, 10931-10934, 1992.
59. Weidner N, Semple JP, Welch WR, and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324, 1-8, 1991.
60. Chrysogelos SA, Yarden RI, Lauber AH, and Murphy JM: Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res Treat 31, 227-236, 1994.
61. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, et al.: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8, 175-182, 2001.
62. Jang M and Pezzuto JM: Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 25, 65-77, 1999.
63. Lostumbo A, Mehta D, Setty S, and Nunez R: Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp Mol Pathol 80, 46-53, 2006.
64. Miller H, Poon S, Hibbert B, Rayner K, Chen YX, and O'Brien ER: Modulation of estrogen signaling by the novel interaction of heat shock protein 27, a biomarker for atherosclerosis, and estrogen receptor beta: mechanistic insight into the vascular effects of estrogens. Arterioscler Thromb Vasc Biol 25, e10-e14, 2005.
65. Lu R and Serrera G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179, 297-304, 1999.
66. Pink JJ and Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56, 2321-2330, 1996.
67. Hamilton A and Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11, 647-663, 2000.
68. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712, 1989.
69. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, and Fuqua SA: Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10, 7490-7499, 2004.
70. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, et al.: The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57, 523-528, 2004.
71. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, et al.: Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163, 207-212, 2001.
72. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, et al.: Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem 48, 1241-1250, 2002.
73. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182, 1987.
74. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, et al.: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50, 4332-4337, 1990.
75. Clark GM and McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51, 944-948, 1991.
76. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AJ, Feldman AL, Assersohn L, et al.: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4, 2002.